Connect with us

Business

Canna-flation – High-End Cannabis Brands are About to Meet Price-Conscious Consumers in a Big Way

Published

on

The cannabis industry consists of different products ranging from flowers, extracts, edibles, and so on. With such a wide variety of products, their categories in the market tend to evolve and change with time. What this means is that some of these products possess tiers and sub-tiers that impact which products rank higher before the consumer. It is therefore important to look at what will make a cannabis product high in demand. Read on as we explore what sets a cannabis product out to consumers who set cannabis prices as the bottom line.

Prices, Purchasing Power, and Options

Cannabis dispensaries are organized to differentiate top-shelf products from generic products on the menus. Branding, marketing, and organization in the dispensary have served as key differentiators used to separate these products. The aim is to ensure that the customers can be attracted to the features, benefits, quality, and other traits of such top-shelf products. This is expected to inform the buying decision of such a customer and direct them to the top products in the dispensary. However, trends have shown that the major factor driving consumers buying decisions in 2022 is cannabis prices.

The purchasing power of a consumer is a very important factor that determines what the consumer can purchase market. This means that cannabis consumers are very conscious of the prices of products in line with their purchasing power. While this is predominantly true, the cannabis industry is such that consumers aim to get maximum satisfaction from their products. This means while also considering prices and their purchasing power, cannabis consumers want to get the most for their money.

Cannabis flower prices on the West Coast plunged recently with the prices of outdoor and greenhouse products dropping by 50% from last year. This means consumers that are very particular about the prices of products now have a bigger net of options to choose from.

Jason Bridges as the head of merchandising with Amuse which is one of the largest cannabis distributors in California. He recently weighed in on the discussion about price-conscious consumers in the cannabis industry. Bridges believe that consumers are more price-conscious now than they were a couple of years ago. He added that consumers are normally willing to pay top dollar for flowers with as high as 30% THC due to their quality and potency. However, a number of small brands now possess flowers with high THC content at low prices. Bridges, therefore, believes this has affected the mindset of consumers to seek products with high THC content and low prices irrespective of brands.

How do these products perform in the market?

What will help you understand this market characteristic of cannabis consumers is how cannabis products perform in mature markets. Headset reported on the popularity of cannabis products in mature markets earlier this year. The results showers that the products are consistently ebb and flow based on consumer performance in the market. As the markets mature, edibles and other products are gradually taking prominence from cannabis flowers which normally dominate the market. Other products such as tinctures, sublingual strips, pre-rolls, and beverages are also becoming important. Canada recorded a stunning 3,000% growth in tinctures and sublingual products over the year.

Distinction across groups of products also affects the prices and performances of such products. As stated earlier, some products easily possess tiers and sub-tiers which perform differently and thus cannot be generalized. Flowers for example according to Bridges possess about five different tiers which are more than that of any product. These tiers have different prices and so are expected to be arranged differently and perform differently. Edibles on the other hand are all within the same price range which means their performance in the market depends on the customer’s preference. Other products like vape cartridges and pre-rolls despite their small distinctions are still similar in performance. This means only flowers possess a wide margin in pricing tiers that might influence the customer’s choice.

BDSA analysis also showed the performance of some products of some of these products in the cannabis market in California from 2021. The product that has recorded the most increase in the vape market is live resins. Resins are gradually becoming a household name in cannabis dispensaries as they are top-shelf products with a top stake in the vape market. The analysis from BDSA shows that live resins make up 30% of vape sales in California in 2021. This was a steady increase.10% in 2019. Presently, live resins have grown to more than 75 percent of top-priced products in that category. This trend of live resins is similar to that of flowers in the market where top-shelf products outperform budget buds.

With more subcategories emerging, differentiation in cannabis prices is set to be a major discussion topic in 2022 as products jockey for top-shelf. Consumers have to decide which products have additional benefits and deserve the premium of higher prices. This category is already seen in the edibles market where consumers willingly pay more for additional functional benefits in the gummies. Gummies that have CBD are 20% higher in price than those without. Nonetheless, they have recorded an increase in sales by 40 percent from 2020 to 2021 according to BDSA. Gummy products with minor cannabinoids such as CBN and CBG are also increasing in popularity and performance in California markets.

Bottom line

The performance of cannabis products in the market has shown that the cannabis industry is not like other industries out there. While predictions can be made on which product should perform more than the other, the onus still lies in the hands of the consumer to choose what he wants. With a wide array of products available to meet the need of the consumer, jockeying for the top shelf has become less definite. Purchasing power and prices might be a strong determinant in some regions while benefits are the major factor for some categories. This means ultimately the products which suit the personal preference and capabilities of the consumer should be expected to perform more. Yet, this too is not set in stone so don’t bet on it.

Source: https://cannabis.net/blog/b2b/cannaflation-highend-cannabis-brands-are-about-to-meet-priceconscious-consumers-in-a-big-way

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News